Device Trial Radar · NCT07432659
Add-On ZIDA Sock Therapy for Overactive Bladder
Last checked: Nov 19, 2026Latest source record: May 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
20
Planned (sponsor's estimate)
Start
Apr 17, 2026
Primary completion
Mar 2028
Study completion Mar 2028
Sponsor
- Lead sponsor
- Medical University of South CarolinaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction; Medtronic
- First posted
- Feb 25, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Many people with overactive bladder (OAB) continue to experience symptoms despite pharmacologic treatment. This study evaluates the use of the ZIDA Control Sock, an FDA-cleared, noninvasive wearable device that delivers mild electrical stimulation near the ankle, as an adjunct to usual care. Adults with OAB-wet who remain symptomatic on stable medication will use the device at home once weekly for 12 weeks while continuing their prescribed therapy. The study collects clinical, patient-reported, and safety information during adjunctive device use.
Conditions
- Overactive Bladder
Interventions
ZIDA Control SockDevice
The ZIDA Control Sock is an FDA-cleared, noninvasive wearable neuromodulation device designed for home use. The device delivers low-level electrical stimulation near the ankle to stimulate peripheral nerves involved in bladder control. In this study, the device is used as an adjunct to usual pharmacologic care.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean change in daily urgency urinary incontinence (UUI) episodes (3-day bladder diary)Time frame: From baseline to at the end of treatment at 12 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Rutledge Tower at Medical University of South Carolina
Charleston, South Carolina · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.